Skip Navigation LinksHome > February 2008 - Volume 27 - Issue 2 > Subconjunctival Bevacizumab Injection for Corneal Neovascula...
doi: 10.1097/ICO.0b013e318159019f
Clinical Science

Subconjunctival Bevacizumab Injection for Corneal Neovascularization

Bahar, Irit MD; Kaiserman, Igor MD, MSc, MHA; McAllum, Penny MBChB, FRANZCO; Rootman, David MD, FRCSC; Slomovic, Allan MA, MD, FRCSC

Collapse Box


Purpose: To report on the clinical use of subconjunctival bevacizumab in patients with corneal neovascularization.

Methods: The charts of 10 consecutive patients with corneal neovascularization who received subconjunctival injections of bevacizumab (2.5 mg/0.1 mL) were reviewed. Digital photographs of the cornea were graded by 2 masked observers for density, extent, and centricity of corneal vascularization. Image analysis was used to determine the area of cornea covered by neovascularization as a percentage of the total corneal area.

Results: No significant ocular or systemic adverse events were observed during 3.5 ± 1.1 months of follow-up. Seven patients showed partial regression of vessels. The extent decreased from 6.0 ± 1.2 (SD) clock hours before the injection to 4.6 ± 1.0 clock hours after bevacizumab injection (P = 0.008). Density decreased from 2.7 ± 0.2 to 1.9 ± 0.3, respectively. (P = 0.007). No change was noticed in the centricity of corneal vessels. Corneal neovascularization covered, on average, 14.8% ± 2.5% (SD) of the corneal surface before the injections, compared with 10.5% ± 2.8% (P = 0.36, t test) after bevacizumab injection. Therefore, bevacizumab decreased corneal neovascularization by 29%.

Conclusions: Short-term results suggest that subconjunctival bevacizumab is well tolerated and associated with a partial regression of corneal neovascularization.

Copyright © 2008 Wolters Kluwer Health, Inc. All rights reserved.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.